# EDGAR Filing Document

**Accession Number:** 0002011674
**File Stem:** 0001213900-25-122504
**Filing Date:** 2025-12
**Character Count:** 14204
**Document Hash:** 9b1d9b53f4dfc33e82ddedf82a75ae21
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-122504.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001213900-25-122504

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13G

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251216

**DATE AS OF CHANGE**: 20251216

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95385
- **FILM NUMBER:** 251577120

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Shen Ethan PhD
- **CENTRAL INDEX KEY:** 0002099921

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13G

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** 15F-5. NO. 508, SEC 7
- **STREET 2:** ZHONGXIAO E RD., NANGANG DIST.
- **CITY:** TAIPEI
- **PROVINCE COUNTRY:** F5
- **ZIP:** 115011

## Exhibit 99.1

**Exhibit 99.1**

**JOINT FILING STATEMENT**

**PURSUANT TO RULE 13d-1(k)**

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

---

| | |
|:---|:---|
| **Dated: 12/16/2025** | **Dated: 12/16/2025** |
| **Ethan Shen** | **Ethan Shen** |
| Signature: | /s/ Ethan Shen |
| Name: | Ethan Shen |
| **Date: 12/16/2025** | **Date: 12/16/2025** |
| **YD Biopharma Holding Limited** | **YD Biopharma Holding Limited** |
| Signature: | /s/ Ethan Shen |
| Name: | Director |
| **Date: : 12/16/2025** | **Date: : 12/16/2025** |
| **EG Biomed Limited** | **EG Biomed Limited** |
| Signature: | /s/ Ethan Shen |
| Name: | Director |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13G

### Under the Securities Exchange Act of 1934

**Issuer:** YD Bio Ltd

**Title of Class of Securities:** Ordinary Shares, par value of US$0.0001 per share

**CUSIP Number:** G98301107

**Date of Event Which Requires Filing of this Statement:** 09/30/2025

**Check the appropriate box to designate the rule pursuant to which this Schedule is filed:**

- [ ] Rule 13d-1(b)

- [ ] Rule 13d-1(c)

- [x] Rule 13d-1(d)

---

| 1. | Names of Reporting Persons<br>Ethan Shen | Names of Reporting Persons<br>Ethan Shen |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>F5 | Citizenship or Place of Organization<br>F5 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>54345011.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>54345011.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>54345011.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>54345011.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>77.1% | Percent of Class Represented by Amount in Row (9)<br>77.1% |
| 12. | Type of Reporting Person (See Instructions)<br>IN | Type of Reporting Person (See Instructions)<br>IN |

**Comment for Type of Reporting Person:** Number in each of Rows 5, 7 and 9 consists of (i) 43,120,858 Ordinary shares held by YD Biopharma Holding Limited and (ii) 11,224,153 Ordinary shares held by EG Biomed Limited. YD Biopharma Holding Limited is a company incorporated in the Cayman Islands and Dr. Shen is the beneficial owner of all of the equity interests issued by YD Biopharma Holding Limited. EG Biomed Limited is a company incorporated in the Cayman Islands and wholly owned by Dr. Shen.
Number in Row 11 is based on a total of 70,521,359 ordinary shares of the Issuer of November 17, 2025 reported in the Issuer's Rule 424(b)(3) Prospectus filed on November 17, 2025.

---

| 1. | Names of Reporting Persons<br>YD Biopharma Holding Limited | Names of Reporting Persons<br>YD Biopharma Holding Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>43120858.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>43120858.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>43120858.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>43120858.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>61.1% | Percent of Class Represented by Amount in Row (9)<br>61.1% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Number in each of Rows 5, 7 and 9 consists of 43,120,858 Ordinary shares held by YD Biopharma Holding Limited. YD Biopharma Holding Limited is a company incorporated in the Cayman Islands and Dr. Shen is the beneficial owner of all of the equity interests issued by YD Biopharma Holding Limited.
Number in Row 11 is based on a total of 70,521,359 ordinary shares of the Issuer of November 17, 2025 reported in the Issuer's Rule 424(b)(3) Prospectus filed on November 17, 2025.

---

| 1. | Names of Reporting Persons<br>EG Biomed Limited | Names of Reporting Persons<br>EG Biomed Limited |
|:---|:---|:---|:---|
| 2. | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] | Check the Appropriate Box if a Member of a Group (See Instructions)<br>(a) [ ] (b) [ ] |
| 3. | SEC Use Only | SEC Use Only |
| 4. | Citizenship or Place of Organization<br>E9 | Citizenship or Place of Organization<br>E9 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 5. | Sole Voting Power<br>11224153.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 6. | Shared Voting Power<br>0.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 7. | Sole Dispositive Power<br>11224153.00 |
| Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person<br>With | 8. | Shared Dispositive Power<br>0.00 |
| 9. | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11224153.00 | Aggregate Amount Beneficially Owned by Each Reporting Person<br>11224153.00 |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) [ ] |
| 11. | Percent of Class Represented by Amount in Row (9)<br>15.9% | Percent of Class Represented by Amount in Row (9)<br>15.9% |
| 12. | Type of Reporting Person (See Instructions)<br>CO | Type of Reporting Person (See Instructions)<br>CO |

**Comment for Type of Reporting Person:** Number in each of Rows 5, 7 and 9 consists of 11,224,153 Ordinary shares held by EG Biomed Limited. EG Biomed Limited is a company incorporated in the Cayman Islands and wholly owned by Dr. Shen.
Number in Row 11 is based on a total of 70,521,359 ordinary shares of the Issuer of November 17, 2025 reported in the Issuer's Rule 424(b)(3) Prospectus filed on November 17, 2025.

---

**Item 1(a). Name of Issuer:**
YD Bio Ltd

**Item 1(b). Address of Issuer's Principal Executive Offices:**
12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan

**Item 2(a). Name of Person Filing:**
Ethan Shen
YD Biopharma Holding Limited
EG Biomed Limited

**Item 2(b). Address of Principal Business Office:**
Ethan Shen: 15 F.-5 No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist. Taipei City 115011, Taiwan
YD Biopharma Holding Limited: c/o YD Biopharma Limited, 12F., No. 3, Xingnan St., Nangang Dist., Taipei City 115001, Taiwan
EG Biomed Limited: 15 F.-5, No. 508, Sec. 7, Zhongxiao E. Rd., Nangang Dist., Taipei City 115011, Taiwan

**Item 2(c). Citizenship:**
Ethan Shen - Taiwan
YD Biopharma Holding Limited - Cayman Islands
EG Biomed Limited - Cayman Islands

**Item 2(d). Title of Class of Securities:**
Ordinary Shares, par value of US$0.0001 per share

**Item 2(e). CUSIP Number:**
G98301107

**Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:**

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e) [ ] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), if filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

**Item 4. Ownership:**

**(a) Amount beneficially owned:**

See Row (9) of each cover page.
Ethan Shen: 54,345,011
YD Biopharma Holding Limited: 43,120,858
EG Biomed Limited: 11,224,153

**(b) Percent of class:**

See Row (11) of each cover page.
Ethan Shen: 77.1%
YD Biopharma Holding Limited: 61.1%
EG Biomed Limited: 15.9%

**(c) Number of shares as to which the person has:**

**(i) Sole power to vote or to direct the vote:**

See Row (5) of each cover page.
Ethan Shen: 54,345,011
YD Biopharma Holding Limited: 43,120,858
EG Biomed Limited: 11,224,153

**(ii) Shared power to vote or to direct the vote:**

See Row (6) of each cover page.
Ethan Shen: 0
YD Biopharma Holding Limited: 0
EG Biomed Limited: 0

**(iii) Sole power to dispose or to direct the disposition of:**

See Row (7) of each cover page.
Ethan Shen: 54,345,011
YD Biopharma Holding Limited: 43,120,858
EG Biomed Limited: 11,224,153

**(iv) Shared power to dispose or to direct the disposition of:**

See Row (8) of each cover page.
Ethan Shen: 0
YD Biopharma Holding Limited: 0
EG Biomed Limited: 0

**Item 5. Ownership of Five Percent or Less of a Class.**

[x] If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary**

Not Applicable

**Item 8. Identification and Classification of Members of the Group**

Not Applicable

**Item 9. Notice of Dissolution of Group**

Not Applicable

**Item 10. Certification:**

—

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Ethan Shen**

**Date:** 12/16/2025

**By:** /s/ Ethan Shen

**Name & Title:** Ethan Shen

**YD Biopharma Holding Limited**

**Date:** 12/16/2025

**By:** /s/ Ethan Shen

**Name & Title:** Director

**EG Biomed Limited**

**Date:** 12/16/2025

**By:** /s/ Ethan Shen

**Name & Title:** Director